Senaparib

Senaparib

Clinical data
Other names	IMP-4297
ATC code	None
Identifiers
IUPAC name 5-fluoro-1-[[4-fluoro-3-(4-pyrimidin-2-ylpiperazine-1-carbonyl)phenyl]methyl]quinazoline-2,4-dione
CAS Number	1401682-78-7
PubChem CID	68389008
DrugBank	DB17163
ChemSpider	103704755
UNII	MNZ4OP95CF
ChEMBL	ChEMBL4802152
Chemical and physical data
Formula	C24H20F2N6O3
Molar mass	478.460 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1CN(CCN1C2=NC=CC=N2)C(=O)C3=C(C=CC(=C3)CN4C5=C(C(=CC=C5)F)C(=O)NC4=O)F
InChI InChI=1S/C24H20F2N6O3/c25-17-6-5-15(14-32-19-4-1-3-18(26)20(19)21(33)29-24(32)35)13-16(17)22(34)30-9-11-31(12-10-30)23-27-7-2-8-28-23/h1-8,13H,9-12,14H2,(H,29,33,35) Key:VBTUJTGLLREMNW-UHFFFAOYSA-N

Senaparib is a drug under investigation for the treatment of cancer. ^[1] It is a PARP inhibitor. ^[2] In January 2025, senaparib was approved for use in China for treatment of advanced epithelial high-grade ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. ^[3]

References

1. "Senaparib - IMPACT Therapeutics". AdisInsight. Springer Nature Switzerland AG.
2. Cai SX, Ma N, Wang X, Guo M, Jiang Y, Tian YE (June 2024). "The discovery of a potent PARP1 inhibitor Senaparib". Molecular Cancer Therapeutics. 24 (1): OF1 –OF9. doi:10.1158/1535-7163.MCT-23-0625. PMID   38920409.
3. "Senaparib Receives NMPA Approval As First-Line Maintenance in Ovarian Cancer". onclive.com. 17 January 2025.